DGAP-News

STRATEC achieves higher sales and improved profitability in 2015 - Seite 3

capacities at STRATEC's location in Switzerland were expanded during 2015.
At the location in Romania, construction of a new building began towards
the end of 2015, and the employees at the site in the United Kingdom moved
to a modern, larger building as the capacity of the old space had been
reached.

STRATEC will continue to be in need of qualified personnel, especially in
development.

STRATEC's Board of Management has an interest in long-term staff retention.
For this reason, employees were given the opportunity in the 2015 financial
year to participate in the success of the company through an employee
participation program, further details of which can be found in our Annual
Report.

Projects and other developments
STRATEC will continue to focus in the current financial year on achieving
further major milestones; important market launches are also scheduled for
2016. Negotiations on additional development and production projects are
ongoing, and platform development is being pushed forward in order to
secure growth on numerous pillars for the future.

For 2016 we expect the proportion of sales from spare parts to remain in
line with the high level achieved in 2015, partly driven by the increased
need for spare parts for recently developed, more complex systems.

The Data Management business unit developed very positively in the 2015
financial year, especially due to an order from a new major customer.

The range of offerings and thus also the foundation for growth of STRATEC
will continue to be strengthened through targeted company acquisitions.

2015 Annual Report
The 2015 Annual Report of STRATEC Biomedical AG has been published on the
company's homepage at www.stratec.com/financial_reports.

Forthcoming dates
The Interim Report as of March 31, 2016, will be published on April 26,
2016.

The Annual General Meeting of STRATEC Biomedical AG will be held in
Pforzheim on June 9, 2016. The invitation to the Annual General Meeting
will be forwarded to STRATEC shareholders in good time ahead of the Annual
General Meeting.

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: [phone]
Fax: [phone]
[e-mail]
www.stratec.com


---------------------------------------------------------------------------

14.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------


Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX


End of News DGAP News Service
---------------------------------------------------------------------------

454185 14.04.2016